Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001013594-25-001422
Filing Date
2025-11-14
Accepted
2025-11-14 12:04:30
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 15960
2 EXHIBIT 1 - AMENDED AND RESTATED JOINT FILING AGREEMENT exh99.htm EX-99 8263
  Complete submission text file 0001013594-25-001422.txt   25944
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Subject) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-89140 | Film No.: 251483236
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 960 SAN CLEMENTE WAY MOUNTAIN VIEW CA 94043
Business Address 960 SAN CLEMENTE WAY MOUNTAIN VIEW CA 94043 650-660-3618
Seven Fleet Capital Management LP (Filed by) CIK: 0002092021 (see all company filings)

EIN.: 333756807 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A